Evidence map›Paper›PMID 39003655›Full record

ReviewJournal of assisted reproduction and genetics2024

Heterotopic ovarian transplantation instead hormonal replacement therapy after radical hysterectomy for cervical cancer: case report and review of literature.

Blandine Courbiere, Laura Miquel, Pauline Bottin, Magali Provansal, Jacqueline Saias-Magnan, Catherine Metzler-Guillemain

Abstract readCase ReportsReview
In one paragraph

Review in Journal of assisted reproduction and genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Blandine CourbiereDepartment of Gynecology-Obstetric and Reproductive Medicine - CECOS, AP-HM, Hôpital La Conception, Marseille, France. blandine.courbiere@univ-amu.fr.ORCID http://orcid.org/0000-0002-1847-4509
Laura MiquelDepartment of Gynecology-Obstetric and Reproductive Medicine - CECOS, AP-HM, Hôpital La Conception, Marseille, France.
Pauline BottinDepartment of Gynecology-Obstetric and Reproductive Medicine - CECOS, AP-HM, Hôpital La Conception, Marseille, France.
Magali ProvansalDepartment of Medical Oncology, Institut Paoli Calmettes, Marseille, France.
Jacqueline Saias-MagnanDepartment of Gynecology-Obstetric and Reproductive Medicine - CECOS, AP-HM, Hôpital La Conception, Marseille, France.
Catherine Metzler-GuillemainDepartment of Gynecology-Obstetric and Reproductive Medicine - CECOS, AP-HM, Hôpital La Conception, Marseille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOnly a few case reports have described heterotopic ovarian tissue transplantation (OTT) with the only objective of restoring ovarian function.

methodsCase report and review of the literature for reporting cases of heterotopic OTT with the only aim of restoring ovarian endocrine function. In a cancer survivor woman with a history of hysterectomy and bilateral oophorectomy for cervical cancer and because she poorly tolerated hormone replacement therapy (HRT), we performed a heterotopic OTT in a pelvic subcutaneous "pocket" after an OT cryostorage of 17 years.

resultsA cyclic ovarian endocrine function started 3 months after OTT with an immediate patient self-described improvement of her quality of life. A second OTT was performed 19 months after, due to hot flushes recurrence and FSH increase. Despite a cyclic endocrine function, progesterone levels have always been low, resulting in a relative hyperoestrogenism state.

conclusionIn the future, the indications of heterotopic OTT could be spread in alternative to HRT. However, our data suggest that the heterotopic graft environment is less favorable to corpus luteum development, and further studies are needed to assay the best site of heterotopic graft, the optimal number of ovarian cortex fragments to graft, and the potential risk of relapse in case of malignant residual disease.

Indexed as

Hormone Replacement TherapyHysterectomyOvaryTransplantation, HeterotopicUterine Cervical NeoplasmsAdultFemaleHumansQuality of LifeCancerEndocrine functionHeterotopic transplantationOvarian cryopreservation

Identifiers

PMID39003655
PMCPMC11405575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.